EAOO 2025: HOYA Vision Care Leads Breakthrough in Children’s Eye Care with New Clinical Evidence on Myopia Management and Launch of visuReal MoveAI Kids Module

  • The longest-running clinical study on myopia management spectacle lenses reinforces effectiveness of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in significantly reducing myopia progression and axial elongation over eight years.[i]

 

  • Two-year observational study in European children finds that DIMS spectacle lenses effectively slowed myopia progression.[ii]

 

  • Study concludes that myopia progression varies depending on astigmatism type.[iii]

 

  • Unveiling of the visuReal MoveAI Kids module, HOYA’s latest innovation designed for children, enabling high accuracy for MiYOSMART spectacle lens centration.

 

23th May 2025 – HOYA Vision Care, a global leader in eye care technology, today presented its latest clinical evidence at the 16th Annual European Academy of Optometry and Optics (EAOO) Conference in Ljubljana, Slovenia. This evidence was shared as part of the company’s 2025 scientific campaign: Exploring New Frontiers in Myopia Management with MiYOSMART*, with new clinical evidence supporting the company’s Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The company also unveiled its new visuReal MoveAI Kids Module, an AI-powered video centration system for fitting children's eyewear, highlighting its commitment to enabling children to lead fuller lives through optimal vision care.

 

HOYA Vision Care shared several updates from ongoing research in myopia management, including eight-year results from the longest-running clinical study on myopia management spectacle lenses. These latest findings demonstrate that wearing MiYOSMART spectacle lenses continuously and for the long-term provides an effective, safe, non-invasive myopia control strategy in children, with maximum benefits achieved through continuous wear.

 

A two-year observational study of 103 European children aged 5–15 years2 indicated that DIMS spectacle lenses are similarly effective in slowing myopia progression in both UK and Hong Kong pediatric populations when comparing the results with existing data.[iv] In UK children wearing DIMS spectacle lenses there was an average change in axial length growth of 0.17±0.19mm and 0.12±0.13mm after one and two years of wear, respectively.

 

A separate study concluded that myopia progression could be variable depending on the types of astigmatism in children wearing DIMS spectacle lenses. The study of 184 children (79 Asian and 105 European) found that astigmatic myopic patients had higher myopia, but patients in the spherical group experienced faster myopic progression.3

 

“The evidence for long-term continuous DIMS spectacle lens wear and the 2-year observational study in a European population demonstrate MiYOSMART’s effectiveness in slowing myopia progression. Combined with our insights into how different astigmatism types can influence myopia management outcomes, this research highlights HOYA Vision Care’s leadership in advancing the understanding of myopia, our continuous innovation in delivering effective solutions globally, and our commitment to paving the way for tailored treatments in children’s eye health worldwide," said  Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care.

 

HOYA Vision Care unveiled their visuReal MoveAI Kids module at EAOO 2025, marking the global debut of its video centration module specifically designed for children. visuReal MoveAI  is a flexible, accurate, and user-friendly portable digital centration solution. With its integrated application, intuitive interface and AI-powered automated detection, visuReal MoveAI makes lens centration fast and easy.[v] The latest addition of the Kids module further supports proper centration of MiYOSMART* spectacle lenses with well-fitted frames to enable effective treatment performance. 

 

“The launch of our specifically-tailored Kids module for visuReal MoveAI reinforces HOYA Vision Care's dedication to superior vision care for children,” said Félix España, Global Instruments Director at HOYA Vision Care. “Optimal spectacle lens centration is especially crucial for myopia management treatment spectacle lenses such as MiYOSMART to ensure the best treatment outcomes for these young patients. We continuously strive to expand the frontiers of vision care by integrating our deep knowledge of global eye care needs and utilizing innovative technology such as AI into HOYA Vision Care’s solutions.”

 

About HOYA Corporation

Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products. HOYA’s divisions and business units research and develop products utilized in the healthcare and information technology fields. In the healthcare field, we provide medical device products such as eyeglasses, medical endoscopes, contact and intraocular lenses, orthopedic implants, surgical/therapeutic devices and medical device reprocessing and disinfection solutions.

In the information technology field, we provide products such as optical lenses, photomasks and blanks used in the manufacturing process for semiconductor and LCD/OLED devices, text to speech, human resources and other software solutions and critical components for the mass memory and cloud storage industries. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 37,000 people.

Learn more about HOYA Corporation
Man with beard smiling at glasses

About HOYA Vision Care

For over 60 years, HOYA Vision Care has been a global leader in the eyeglass lens industry. With a presence in over 50 countries, HOYA Vision Care has a leading position in myopia management category and a proven expertise in advanced lens designs, high performance photochromic technologies and high-quality AR coatings.

HOYA Vision Care’s solid market portfolio includes SEIKO and PENTAX optical lenses, as well as innovative products such as MiYOSMART myopia control lenses for children, Hoyalux MySelf individualized progressive lenses and the Sensity series of photochromic coatings. The company employs over 20.000 employees worldwide with large scale production facilities in Asia, Europe and the US and 30 local Rx laboratories globally.

Learn more about HOYA Vision Care
Man with beard smiling at glasses

For further information contact:

Pamela Pedrucci

PR, Media, and External Comms Director HOYA Vision Care

pamela.pedrucci@hoya.com

Follow HOYA Vision Care on LinkedIn 

Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.

 

References:

  • Leung TW, et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Poster number A0113. Presented 6th May at ARVO 2025.
  • Saunders KJ, et al. Multi-Site Observational Study of Defocus Incorporated Multiple Segments (DIMS) spectacle lenses in UK children: 2-year results. Presented 18th May at EAOO 2025.
  • Hoogendoorn J, et al. Influence of Different Types of Astigmatism on Myopia Progression in Children Wearing Defocus Incorporated Multiple Segments Spectacles. Presented 17th May at EAOO 2025.
  • Lam CSY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. Br J Ophthalmol. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739/.
  • HOYA Vision Care. visuReal Moveᴬᴵ. Available at https://www.hoyavision.com/uk/your-business-partner/deliver-the-best-patient-care/hoya-visureal-move%E1%B4%AC%E1%B4%B5/